Avanir’s Alzheimer’s Agitation Drug Hits Primary Goal in PIII

March 26, 2019
Avanir Pharmaceuticals’ investigational agent AVP-786 (deudextromethorphan hydrobromide + quinidine sulfate) showed a significant improvement in Alzheimer’s agitation at one of the two doses tested in a PIII study, according to topline data released on March 25. The US subsidiary of...read more